2007
DOI: 10.1016/j.jchromb.2006.07.004
|View full text |Cite
|
Sign up to set email alerts
|

Antibody production: Polyclonal-derived biotherapeutics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
42
0

Year Published

2007
2007
2017
2017

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 60 publications
(43 citation statements)
references
References 39 publications
0
42
0
Order By: Relevance
“…In contrast, there are a wealth of PAbs with a range of different specificities and affinities. Currently, polyclonal Ab therapeutics are widely used in medicine for the neutralization of viruses and toxins and for replacement therapy in patients with immunoglobulin deficiencies [5]. This emphasises the need for Abs that allow for the elution of bound Abs using fairly mild elution reagents.…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, there are a wealth of PAbs with a range of different specificities and affinities. Currently, polyclonal Ab therapeutics are widely used in medicine for the neutralization of viruses and toxins and for replacement therapy in patients with immunoglobulin deficiencies [5]. This emphasises the need for Abs that allow for the elution of bound Abs using fairly mild elution reagents.…”
Section: Introductionmentioning
confidence: 99%
“…One incarnation of the passive approach is the use of intravenous immune globulin (IGIV) such as Gamunex (Talecris Biotherapeutics, North Carolina) or Gammagard (Baxter, Illinois), which are 10% w/v liquid suspensions of purified human IgG [38]. Numerous studies have reported both in vitro [39,40] and in vivo efficacy of IGIV treatment in murine models and patients with AD [41][42][43][44].…”
Section: Passive Intravenous Immunization With Enriched Immune Globulinmentioning
confidence: 99%
“…9 This paper models a synthetic Protein A based chromatographic capture of antibodies from sheep serum, an option that is being considered by Protherics UK Limited (Blaenwaun, Ffostrasol, Llandysul, Wales, UK) as an initial purification step for the manufacture of the FDA-approved rattlesnake anti-venom CroFab  . 10,11 The synthetic adsorbent step was simulated using the Thomas model, 12 which was then used to predict the amounts of antibody that are captured and lost upon application of the ovine serum to the column. Assumed data values used to populate the model were obtained from Protherics.…”
Section: Illustrative Industrial Case Studymentioning
confidence: 99%